GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 19 Dec 2016.
Cancer susceptibility candidate 3
MLN51, BTZ, Barentsz, metastatic lymph node 51, CASC3
The product of this gene is a core component of the exon junction complex (EJC), a protein complex that is deposited on spliced mRNAs at exon-exon junctions and functions in nonsense-mediated mRNA decay (NMD). The encoded protein binds RNA and interacts with two other EJC core components. It is predominantly located in the cytoplasm, but shuttles into the nucleus where it localizes to nuclear speckles. [provided by RefSeq, Jul 2008] (from
NCBI)
Sponsored links
Top mentioned proteins:
CAN, Y14, caspase-3, Magoh, V1a
Papers using
MLN51
antibodies
Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors
Supplier
In Advances in Hematology, 2006
... BTZ under investigation were reconstituted using a sterile NaCl 0.9% solution (in deuterated water D2O, Merck) to produce the suitable ...
Papers on
MLN51
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
New
Nagoya, Japan. In Int J Hematol, Jan 2016
To determine the optimal dosing schedule of once weekly bortezomib (BTZ) combined with lenalidomide (LEN) and dexamethasone (DEX), especially in the outpatient setting, we conducted a phase I dose escalation study.
An implantable smart magnetic nanofiber device for endoscopic hyperthermia treatment and tumor-triggered controlled drug release.
New
Chŏnju, South Korea. In Acta Biomater, Jan 2016
This device is achieved using a two-component smart nanofiber matrix from monodisperse iron oxide nanoparticles (IONPs) as well as bortezomib (BTZ), a chemotherapeutic drug.
Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment.
New
Boston, United States. In Blood, Jan 2016
Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significant increase in progression-free survival (PFS) vs placebo plus bortezomib and dexamethasone (Pbo-BTZ-Dex) in patients with relapsed or relapsed and refractory MM in the phase 3 PANORAMA 1 trial.
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
New
Tianjin, China. In Cancer Biol Med, Dec 2015
OBJECTIVE: To investigate the effects of CAL-101, particularly when combined with bortezomib (BTZ) on mantle cell lymphoma (MCL) cells, and to explore its relative mechanisms.
Thrombotic microangiopathy associated with proteasome inhibitors.
Review
New
Iowa City, United States. In Clin Kidney J, Oct 2015
Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome pathway, indicated in treatment of patients with multiple myeloma.
Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.
Nagoya, Japan. In Blood Cancer J, 2014
Bortezomib (BTZ), a proteasome inhibitor, is widely used in the treatment of multiple myeloma (MM), but a fraction of patients respond poorly to this agent.
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Review
Charleston, United States. In Adv Cancer Res, 2014
The debut of the proteasome inhibitor bortezomib (Btz; Velcade®) radically and immediately improved the treatment of multiple myeloma (MM), an incurable malignancy of the plasma cell.
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Review
Amsterdam, Netherlands. In Arthritis Res Ther, 2014
The antiproliferative capacity of proteasome inhibitors (PIs) has received considerable attention given the success of their first prototypical representative, bortezomib (BTZ), in the treatment of B cell and plasma cell-related hematological malignancies.
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Review
Detroit, United States. In Curr Cancer Drug Targets, 2013
In 2003, Bortezomib (BTZ) became the first proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA).
Metastatic lymph node 51 and fibroblast-like synoviocyte hyperproliferation in rheumatoid arthritis pathogenesis.
Review
GeneRIF
South Korea. In Rheumatol Int, 2011
MLN51 is a key factor in fibroblast-like synoviocyte hyperplasia of rheumatoid arthritis patients.
RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling.
Impact
Cambridge, United States. In Nat Cell Biol, 2011
Using proteomics approaches, we have identified BLZF1 and CASC3 as further substrates targeted by tankyrase and RNF146 for degradation.
Assembly of endogenous oskar mRNA particles for motor-dependent transport in the Drosophila oocyte.
Impact
Heidelberg, Germany. In Cell, 2009
Our analysis uncovers a role for the EJC component Barentsz in recruiting Tropomyosin II (TmII) to oskar particles in the ooplasm and reveals that TmII is required for kinesin binding to the RNPs.
The exon-junction-complex-component metastatic lymph node 51 functions in stress-granule assembly.
GeneRIF
Strasbourg, France. In J Cell Sci, 2007
MLN51 is recruited into cytoplasmic aggregates known as stress granules (SGs) together with the SG-resident proteins.
Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA.
Impact
GeneRIF
Århus, Denmark. In Science, 2006
crystal structure of a tetrameric exon junction core complex containing the DEAD-box adenosine triphosphatase eukaryotic initiation factor 4AIII bound to an ATP analog, MAGOH, Y14, a fragment of MLN51, and a polyuracil mRNA mimic
The crystal structure of the exon junction complex reveals how it maintains a stable grip on mRNA.
Impact
Heidelberg, Germany. In Cell, 2006
The complex is formed by the association of four proteins (eIF4AIII, Barentsz [Btz], Mago, and Y14), mRNA, and ATP.
Association of the breast cancer protein MLN51 with the exon junction complex via its speckle localizer and RNA binding module.
GeneRIF
Illkirch-Graffenstaden, France. In J Biol Chem, 2004
data demonstrate that metastatic lymph node(MLN)51 protein associates with exon junction complex in the nucleus and remains stably associated with messenger RNA in the cytoplasm
An eIF4AIII-containing complex required for mRNA localization and nonsense-mediated mRNA decay.
Impact
GeneRIF
Cambridge, United Kingdom. In Nature, 2004
identification of eIF4AIII and Barentsz as components of a conserved protein complex that is essential for mRNA localization in flies and nonsense-mediated mRNA decay in mammals
